Denmark considered that the proposed testing regime to demonstrate freedom from extraneous agents was insufficient to ensure that Bovilis BVD/ Bovilis BVD-MD would not interfere with their national eradication campaigns for certain animal diseases and that, therefore, the benefit/ risk assessment for Bovilis BVD/ Bovilis BVD-MD was unfavourable, authorisation of the product representing a potential serious risk to animal health.
Danska je menila, da predlagani režim testiranja za predstavitev odsotnosti tujih snovi v zadostni meri ne zagotavlja, da zdravilo Bovilis BVD/ Bovilis BVD- MD ne bi oviralo nacionalnih programov za izkoreninjenje določenih bolezni živali ter da razmerje med koristmi in tveganji za zdravilo Bovilis BVD/ Bovilis BVD- MD ni ugodno, tako da bi morebitna odobritev dovoljenja za promet z zdravilom lahko pomenila možno resno tveganje za zdravje živali.